	US 12,458,673 B2
	Use of specific phages for the treatment of nontuberculosis mycobacteria (NTM) infections
Graham F. Hatfull, Pittsburgh, PA (US); Carlos Andres Guerrero, Pittsburgh, PA (US); and Rebekah Marie Dedrick, Glenshaw, PA (US)
Assigned to University of Pittsburgh—Of the Commonwealth System of Higher Education, Pittsburgh, PA (US)
Filed by University of Pittsburgh—Of the Commonwealth System of Higher Education, Pittsburgh, PA (US)
Filed on Mar. 8, 2022, as Appl. No. 17/689,096.
Application 17/689,096 is a continuation of application No. PCT/US2020/059388, filed on Nov. 6, 2020.
Claims priority of provisional application 62/931,948, filed on Nov. 7, 2019.
Prior Publication US 2022/0193160 A1, Jun. 23, 2022
Int. Cl. A61K 35/76 (2015.01); A61P 31/04 (2006.01); C12Q 1/18 (2006.01)

CPC A61K 35/76 (2013.01) [A61P 31/04 (2018.01); C12Q 1/18 (2013.01)]

1 Claim

1. A composition comprising:

bacteriophages BPsΔ33HTH-HRM10, Muddy, ZoeJΔ45; and

one or more bacteriophages selected from Adephagia, Adjutor, Alma, BPs, BPsΔ33, BPsΔ33HTH_HRM10, BPs_HRM2, BPsΔ33HTH_HRM^GD03BPsΔ33HTH HRM^GD10Bxb1, Cain, Charlie, Che9c, D29, Elmo_HRM^smeg, FionnbharthΔ45Δ47, Fred313_cpm1, Isca, Isca_HRM^smegItos, Island3, Jeon, Larva, Muddy_HRM^GD04, Nanosmite, Peaches, Pegleg, ZoeJ, and Faith1Δ38-40.